Medtronic announced the broad U.S. commercial launch of the MiniMed 780G system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed systems. Following U.S…. read more.
Patients with diabetes have an increased risk of complications after stent implantation, according to a study from Karolinska Institutet in Sweden published in Diabetes Care. The study emphasises… read more.
Abbott has initiated a medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the United States after internal testing determined that some… read more.
Orforglipron , an investigative and oral GLP-1 drug, appears to enable adults with obesity and Type 2 diabetes to achieve significantly more weight loss and improvement in blood… read more.
A widely prescribed diabetes drug may be sabotaging one of the most trusted strategies for preventing the disease: exercise. That is the conclusion of a Rutgers-led study published in The Journal… read more.
Obese or overweight non-diabetic adults with atrial fibrillation (Afib) who take the diabetes medication metformin after a catheter ablation are more likely to remain free of AFib for… read more.
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that… read more.
People with type 1 diabetes achieved significantly better long-term blood glucose when their levels were monitored by healthcare professionals in real time, via a sensor under the skin,… read more.
A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels in diabetic patients and increasing exercise capacity for better health… read more.
Nearly one-third of people with type 2 diabetes (T2D) in an Indian cohort achieved remission through an intensive lifestyle intervention program, according to a new study publishing October… read more.
The FDA has accepted for expedited review the supplemental biologics license application (sBLA) for Tzield (teplizumab-mzwv) to delay the progression of stage 3 type 1 diabetes (T1D) in… read more.
MannKind Corporation announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (insulin human) Inhalation Powder in children and adolescents living with… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
